Klinika Ambroziak Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The research site is advancing treatments for atopic dermatitis, a chronic immune‑mediated skin disorder, by testing new therapeutic options that aim to improve safety and effectiveness for patients of various ages.
- Evaluation of novel biologic agents for moderate‑to‑severe atopic dermatitis
- Safety assessment of emerging therapies in adolescent patients
- Development of long‑term disease control strategies
These studies seek to broaden available options for individuals living with eczema, and Klinika Ambroziak in Warsaw plays a key role in bringing innovative care to the community.
Skin and Connective Tissue Diseases
Focused on actinic keratosis of the face and scalp, the clinic evaluates topical treatments designed to clear precancerous lesions and reduce the risk of progression.
- Topical ointment efficacy for actinic keratosis on facial and scalp areas
- Comparative analysis of lesion clearance rates versus standard care
- Optimizing outcomes with larger treatment fields
By targeting early skin changes, the research aims to improve patient outcomes and support preventive dermatology practices at the Warsaw facility.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Amgen Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinika Ambroziak Sp. z o.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.7881 in adult patients with moderate-to-severe atopic dermatitis | Bioprojet Pharma | Phase II | Not Recruiting | Aug 2023 | Jun 2024 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bp1.7881A | 1 | Unknown | 2023-08-11 | 2023-08-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.